BioCryst (BCRX) Pharmaceuticals announced that the National Institute of Drug and Food Surveillance, INVIMA, in Colombia has granted approval for oral, once-daily ORLADEYO for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older. BioCryst has an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO in the pan-Latin America region. Under the terms of the agreement, Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in LATAM. ORLADEYO has previously been approved in this region by regulatory agencies in Chile, Argentina, Brazil, Mexico and Peru.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst achieves reimbursement for ORLADEYO across major European countries
- BioCryst Extends Consulting Agreement with Former CFO
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst highlights real-world data on ORLADEYO in HAE attacks
- BioCryst presents new real-world evidence on ORLADEYO in severe HAE